2005
DOI: 10.7326/0003-4819-142-10-200505170-00007
|View full text |Cite
|
Sign up to set email alerts
|

Treatment Alternatives for Chronic Hepatitis B Virus Infection: A Cost-Effectiveness Analysis

Abstract: Neither lamivudine nor adefovir monotherapy is cost-effective in chronic HBV infection. However, a hybrid salvage strategy reserving adefovir only for lamivudine-associated viral resistance may be highly cost-effective across most health care settings. Interferon therapy may still be preferred in health care systems with limited resources, especially in those serving populations with a high prevalence of HBeAg-negative HBV.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

6
133
0
2

Year Published

2006
2006
2012
2012

Publication Types

Select...
7
1
1

Relationship

0
9

Authors

Journals

citations
Cited by 118 publications
(141 citation statements)
references
References 113 publications
6
133
0
2
Order By: Relevance
“…To test the impact of varying utility scores for liver complications on our cost-effectiveness results, a different set of published utility tariff values was also used 38 ; these values were not chosen for reference case analyses because their utility scores were primarily derived from surveys on hepatitis C patients.…”
Section: Sensitivity Analysesmentioning
confidence: 99%
“…To test the impact of varying utility scores for liver complications on our cost-effectiveness results, a different set of published utility tariff values was also used 38 ; these values were not chosen for reference case analyses because their utility scores were primarily derived from surveys on hepatitis C patients.…”
Section: Sensitivity Analysesmentioning
confidence: 99%
“…Its use, however, is hampered by the emergence of resistance [4] , and a report from Iran showed a good biochemical control in only half of the patients after one year of treatment [17] . Cost-effectiveness analysis of alfa-interferon has shown contradictory results for health care systems with tight budgetary constraints [18,19] . Lamivudine or adefovir monotherpay is not considered cost-effective [19] , while data are lacking on entecavir and telbivudine.…”
Section: Discussionmentioning
confidence: 99%
“…It provides a common unit to allow comparisons between different disease groups or intervention programmes (Weinstein, Torrance, & McGuire, 2009). This method is particularly useful in the analysis of preventive health programmes, such as anti-viral treatment in CHB patients (Kanwal et al, 2005;Sullivan et al, 2007;Sun et al, 2007;Yuan et al, 2008).…”
Section: Preference-based Measure (Utility) Of Hrqolmentioning
confidence: 99%
“…QALYs have been applied to different diseases or intervention programs, for instance, treatment of coronary heart disease and screening for breast cancer (Chan, Nallamothu, Gurm, Hayward, & Vijan, 2007;Wong, Kuntz, Cowling, Lam, & Leung, 2007). Information on the preference values of different CHB states can be combined with life years gain in the evaluation of the cost-effectiveness of different anti-viral treatment strategies for CHB (Kanwal et al, 2005;Sullivan et al, 2007;Veenstra et al, 2008;Yuan et al, 2008).…”
Section: Preference-based Measure (Utility) Of Hrqolmentioning
confidence: 99%